Brian Barnes, PhD and Nathan Taylor appointed CEO and President; Don Brown stepping down as CEO and will remain on the Board of Directors.

HOPKINTON, MA / ACCESS Newswire / October 2, 2025 / Isto Biologics, a regenerative MedTech company specializing in orthobiologic solutions, announced today a planned leadership transition as the Company embarks on its next phase of growth under new ownership by Keensight Capital.

Effective immediately, Brian Barnes, PhD, previously President of Isto Biologics, has been appointed Chief Executive Officer. Nathan Taylor, formerly Chief Revenue Officer, has been appointed President. Don Brown, who led Isto's significant expansion over the past decade as CEO, will transition to the Company's Board of Directors, continuing to support strategic initiatives and long-term growth.

"I am honored to assume the role of CEO at such an exciting time for Isto," said Dr. Barnes. "We have an extraordinary opportunity to accelerate innovation and expand our reach to more patients worldwide."

Dr. Barnes has been a central part of Isto's growth story. He joined Arteriocyte Medical Systems (currently dba Isto Biologics) in 2009 to direct clinical affairs and has since led many departments, including Regulatory and Quality Affairs, Operations and Manufacturing, R&D, and Medical Education. He has driven the expansion of Isto's portfolio with innovative and novel solutions, focusing on surgeon insights to ensure each product addresses real clinical needs. As CEO, Dr. Barnes will lead the company's strategic direction to expand Isto's presence in the global orthopedic and regenerative biologics marketplace.

Nathan Taylor has been with the organization since 2009, advancing through a series of sales leadership roles that positioned him to guide Isto's commercial success. He has been instrumental in scaling the business, building strong partnerships, and driving the Company's expansion in a highly competitive market. As President, he will continue shaping Isto's strategy and leading commercial operations to deliver on its mission of helping patients heal faster.

These leadership changes build on the foundation established under Don Brown's tenure as CEO.

"We're excited for the future and are well-positioned to carry this momentum forward at Isto Biologics," said Dr. Barnes. "We remain committed to advancing innovation and expanding our impact for patients and partners worldwide."

About Brian Barnes

Brian Barnes, PhD, Chief Executive Officer
Dr. Barnes has been with Isto Biologics since 2009, holding leadership roles across clinical affairs, regulatory and quality, operations, manufacturing, and R&D. He became Chief Technology Officer in 2016 and was promoted to President in 2019, before being named Chief Executive Officer in 2025. Over his tenure, he has helped expand Isto's orthobiologics portfolio with surgeon-focused innovation and guided the company's growth into a leading pure-play biologics provider. Dr. Barnes earned a Ph.D. in Integrative Physiology from the Karolinska Institute in Stockholm, Sweden, home of the Nobel Prize, and a Master's degree in Exercise Physiology from Ball State University. He is recognized for his collaborative, integrity-driven leadership style, which has supported Isto through both rapid expansion and industry challenges.

About Nathan Taylor

Nathan Taylor, President
Mr. Taylor has been with Isto Biologics since 2009, advancing through a series of commercial leadership positions with increasing responsibility. He served as Vice President of Sales and Marketing before being promoted to Chief Revenue Officer in 2024, and was appointed President in 2025. During his tenure, Isto Biologics has achieved significant growth, with company revenue expanding more than fivefold since 2017. This trajectory reflects his ability to build high-performing teams, cultivate customer partnerships, and drive strategic execution in a highly competitive market. Mr. Taylor holds a Bachelor's degree in Business Administration from the Richard T. Farmer School of Business at Miami University.

About Isto Biologics
Isto Biologics is a regenerative MedTech company developing and manufacturing orthobiologic products to help patients heal faster. With a complete portfolio of autologous therapies, synthetic bone grafts, and allograft tissue solutions, Isto's products are used in more than 15,000 surgical procedures per month across 400+ hospitals and clinics in the U.S.

Media Contact:
Jessica Kemp
Marketing Director
774-230-7125 / jkemp@istobiologics.com

SOURCE: Isto Biologics